Lanadelumab
- Generic Name
- Lanadelumab
- Brand Names
- Takhzyro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1426055-14-2
- Unique Ingredient Identifier
- 2372V1TKXK
- Background
Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. The FDA and EU granted the designation of priority review, breakthrough therapy and orphan drug for rare diseases based on the results of the repor...
- Indication
Lanadelumab is indicated for the prophylaxis treatment to prevent attacks in adult and pediatric patients aged 2 years and older with hereditary angioedema.
...
- Associated Conditions
- Acute attacks of hereditary angioedema, Recurrent Angioedema
- Associated Therapies
- -
New Treatments for Hereditary Angioedema
Hereditary angioedema (HAE) treatment options have expanded with eight FDA-approved medications and more in development. HAE, a rare genetic disorder, involves C1 esterase inhibitor gene mutations causing severe swelling. While no cure exists, therapies like kallikrein inhibitors (Lanadelumab-flyo, Berotralstat, Ecallantide) and C1 esterase inhibitors (Cinryze, Haegarda, Ruconest, Berinert) aim to prevent and manage attacks.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath